₹2.62
(Market cap
₹1,746 Cr
Recently Viewed
Clear AllMarket cap
₹1,746 Cr
Revenue (TTM)
₹1,119 Cr
P/E Ratio
216.7
P/B Ratio
1.7
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹8 Cr
ROE
0.2 %
ROCE
7.1 %
Industry P/E
50.33
EV/EBITDA
14
Debt to Equity
0.4
Book Value
₹92.9
EPS
₹0.7
Face value
10
Shares outstanding
108,009,770
CFO
₹358.81 Cr
EBITDA
₹1,032.68 Cr
Net Profit
₹412.86 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Shalby
| -20.5 | 15.7 | -4.4 | -19.7 | 3.4 | 5.5 | -- |
|
BSE Healthcare
| 0.1 | 2.8 | 5.2 | 3.6 | 24.0 | 13.2 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Shalby
| -11.8 | -23.6 | 100.7 | 7.0 | 29.5 | 17.5 | -36.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Shalby
|
162.1 | 1,746.0 | 1,118.9 | 4.0 | 5.9 | 0.8 | 216.7 | 1.7 |
| 233.2 | 3,704.4 | 1,041.9 | 96.4 | 12.0 | 11.5 | 38.3 | 3.2 | |
| 684.3 | 35,457.6 | 4,461.2 | 397.5 | 13.4 | 9.1 | 108.4 | 7.7 | |
| 461.2 | 14,616.5 | 1,976.2 | 160.7 | 14.1 | 6.7 | 116 | 7.4 | |
| 578.3 | 8,623.7 | 2,478.2 | 24.7 | 8.4 | 4.2 | 455.1 | 6.4 | |
| 400.5 | 3,677.0 | 1,451.5 | 182.9 | 15.5 | 29.2 | 20.1 | 5.3 | |
| 1,292.2 | 8,465.2 | 1,433.4 | 188.7 | 17.4 | 13.8 | 44.9 | 5.7 | |
| 5,637.8 | 6,174.1 | 1,529.9 | 235.8 | 21.2 | 20.7 | 26.2 | 4.9 | |
| 1,293.8 | 13,159.5 | 1,613.3 | 259.9 | 23.0 | 17.3 | 51.1 | 8.3 | |
| 740.9 | 7,141.3 | 1,089.4 | 165.1 | 17.4 | 10.2 | 42.7 | 4.1 |
1 min read•By Research Desk
Shalby Limited: Information Analysis
6 min read•By Yash Rohra
Shalby Limited operates multi-specialty hospitals primarily in India, North America, Japan, and Indonesia. The company offers arthroscopy, arthroplasty, cardiology, cardiothoracic and vascular surgery, cosmetic and aesthetic, dental cosmetic and... implantology, emergency medicine, endocrinology, endoscopy and laparoscopy, ENT surgery, gastroentero surgery, gastroenterology, general medicine and surgery, hair transplant, liver transplant, dermatology, psychiatry, urology, anesthesia, and hip and knee joint replacement services. It also provides infectious disease, infertility and IVF, intensive and critical care, maxillofacial surgery, nephrology, neurosurgery, neurology, obesity surgery, obstetrics and gynecology, oncology, oncosurgery, ophthalmology and glaucoma, orthopedic and trauma, pediatric orthopedic, pathology and microbiology, pediatrics and neonatology, plastic surgery, pulmonology and chest, radiology and imaging, rheumatology, trauma, spine surgery, and urosurgery services, as well as organ donation. In addition, it offers outpatient services, as well as provides educational programs for paramedical students and other healthcare professionals; and homecare services, such as ICU at home, diagnostics, attendants, doctor visit, nursing care, physiotherapy, pharmacy, and medical equipment. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is headquartered in Ahmedabad, India. Read more
Incorporated
2004
Chairman
Vikram Shah
Managing Director
Vikram Shah
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Shalby Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Shalby Ltd is ₹162.07 (NSE) and ₹161.65 (BSE) as of 22-Apr-2026 IST. Shalby Ltd has given a return of 3.41% in the last 3 years.
The P/E ratio of Shalby Ltd is 216.70 times as on 22-Apr-2026, a 331 premium to its peers’ median range of 50.33 times.
The P/B ratio of Shalby Ltd is 1.74 times as on 22-Apr-2026, a 76 discount to its peers’ median range of 7.11 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
342.20
|
2.15
|
|
2024
|
30.57
|
2.57
|
|
2023
|
21.33
|
1.56
|
|
2022
|
23.31
|
1.44
|
|
2021
|
25.69
|
1.31
|
The 52-week high and low of Shalby Ltd are Rs 274.70 and Rs 125.82 as of 22-Apr-2026.
Shalby Ltd has a market capitalisation of ₹ 1,746 Cr as on 22-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Shalby Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.